pH-Shiftable Nanoparticles for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents like oxaliplatin face challenges such as multidrug resistance, severe side effects, and limited targeting to tumor sites due to rapid distribution and degradation, while microRNA therapy is hindered by instability and off-target effects.
Innovation Solution
Development of pH-shiftable nanoparticles with a cationic target molecule and an acid-detachable polymer coating, incorporating microRNAs or drugs like oxaliplatin, which accumulate in cancer cells at acidic pH, enhancing cellular uptake and nucleus targeting through peptide-conjugated liposomes and solid lipid nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents like oxaliplatin are used, then antitumor activity is achieved, but multidrug resistance and severe side effects occur due to non-selective distribution
Solution Approach 1:
The patent segments the drug delivery system into multiple functional components: pH-sensitive polymer coating for tumor targeting, peptide conjugates for cell penetration and nuclear targeting, and the therapeutic agent core. This segmentation allows each component to perform its specific function independently, achieving selective tumor targeting while reducing systemic side effects
Solution Approach 2:
The patent uses pH-sensitive polymers and peptide conjugates as intermediaries between the chemotherapeutic agent and cancer cells. These intermediaries enable selective accumulation at acidic tumor sites and facilitate cellular uptake, while preventing premature drug release and reducing exposure of normal tissues to the therapeutic agent
2Speed
If oxaliplatin is administered systemically, then drug distribution occurs rapidly, but arrival at target tumor sites is hampered by high volume of distribution
Solution Approach 1:
The patent changes the physical and chemical parameters of the drug delivery system by using pH-sensitive polymers that respond to the acidic microenvironment of tumors. This parameter change enables the nanoparticle to maintain stability in circulation (physiological pH) while triggering drug release specifically at the tumor site (acidic pH), thereby improving target site delivery despite rapid systemic distribution
Solution Approach 2:
The patent applies preliminary action by pre-conjugating peptides with tumor-targeting and cell-penetrating properties to the nanoparticle surface before administration. This preliminary functionalization ensures that the nanoparticle is pre-equipped with targeting capabilities, allowing it to actively seek and accumulate at tumor sites rather than relying on passive distribution
3Reliability
If microRNA is used for therapy, then tumor suppression is achieved, but instability and rapid degradation occur in biological systems
Solution Approach 1:
The patent employs a nested structure where microRNA is encapsulated within the nanoparticle core, which is further protected by the pH-sensitive polymer coating. This multi-layer nesting provides physical protection against nucleases and other degradation factors in biological systems, significantly enhancing microRNA stability while maintaining its tumor suppressive function
4Duration of action of stationary object
If PEG-modified nanocarriers are used, then systemic circulation time is increased, but uptake into cancer cells is limited
Solution Approach 1:
The patent introduces dynamic responsiveness by using pH-sensitive polymers that change their conformation and properties in response to pH changes. The nanoparticle maintains a PEG-like stealth surface at physiological pH for prolonged circulation, but undergoes a conformational change at acidic tumor sites to expose cell-penetrating peptides, thereby achieving both long circulation time and efficient cancer cell uptake
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively increase drug delivery and microRNA uptake in cancer cells, reducing side effects and enhancing antitumor efficacy by targeting specific pathways, inducing apoptosis, and suppressing drug resistance and metastasis.
Implementation Method 1
an outer layer, surrounding outside of the nanoparticle core, the outer layer is coating with an acid-detachable polymer, the acid-detachable polymer have the characteristic of responding to acidic pH
Implementation Method 2
the cationic target molecule of the nanoparticle core and the acid-detachable polymer of the outer layer, which form a space and charge barrier via the electrostatic interaction
Data Source
AI summary
At present, there is a great need for the development of new tumor pH-shiftable nanoparticles that are effective to reduce side effects, enhance active tumor focusing, improve the cellular uptake, and nuclear/cytoplasmic targeting of chemotherapy and gene therapeutic. Hence, we designed novel solid lipid nanoparticles (SLN) and liposomes (Lip) to deliver microRNA and antineoplastic agent, respectively. The designed SLN and liposomes incorporating microRNA and anticancer drugs in the core, which is surrounded by lipids modified with peptide T (a ligand plus a cell-penetrating peptide) and a nucleus-targeted sequence of peptide R as the inner shell. Moreover, coating a pH-responsive polymer (PGA-PEG) on the outer layer of Lip-TR (PGA-Lip-TR) and SLN-T (PGA-SLN-T) can protect the peptide T and R from degradation by peptidases during systemic circulation and enhance directing to the acidic tumor sites. Collectively, these pH-shiftable nanoparticles may provide a novel and potential strategy for anticancer therapy.